Manufacturing

Specialized in liquid pharmaceuticals: Blow-Fill-Seal (BFS) technology and Nasal Spray.

Read More

Development

Your partner in bringing medical innovation to the market.

Read More

About Curida

Highly skilled Development and Manufacturing Organization with ambitions.

Read More

Contact Curida

Pharmaceutical Development or Manufacturing needs?

Contact Us

Operational Excellence in Pharmaceuticals since 1974

Curida is a Contract Development and Manufacturing Organization (CDMO) within the Pharmaceutical industry, based in Norway.

Curida has core competency in state-of-the-art manufacturing of Liquid Pharmaceuticals based on sterile unit-dose Blow-Fill-Seal (BFS) technology and Nasal Spray. The development expertise covers the full service for the development of nasal drug products, and experience on operational excellence is spanning more than 40 years. Curida has produced BFS products since 1989 and offers over three decades of know-how in this technology. Customers range from small start-ups and early stage Biotech companies to Big Pharma.

Curida is a part of an exciting and growing life science sector in Norway, and our vision is to be the National Centre for Industrialization of Medical Innovation. Curida is an active partner and member of Oslo Cancer Cluster.

Latest News

Curida to attend CPhI in Frankfurt October 24-26th.

Published: 18 Sep 2017

This year the CPhI Worldwide event will be arranged in Frankfurt on October 24-26th. Curida will be present with a business development team including CEO Leif Rune Skymoen. You can meet us at stand number 110B68 which we share with […]

Read More
 

Leif Rune Skymoen, CEO of Curida, shared the scene with Norwegian business leaders at the Confederation of Norwegian Enterprise (NHO) Annual Ambassador Dinner

Published: 30 Aug 2017

On Tuesday August 22nd, Leif Rune Skymoen, CEO of Curida, gave a lecture and participated in a panel debate at the Confederation of Norwegian Enterprise (NHO) Annual Ambassador Dinner. Mr Skymoen discussed how Norway could build a significant life science […]

Read More